Menin inhibitors emerge as new treatment for advanced AML

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Venkata Lokesh BattulaClinton YamA multidisciplinary team of researchers at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center has been awarded a $7.3 million grant from the U.S. Department of Defense to fund a novel clinical trial targeting one of the most aggressive and hard-to-treat forms of breast cancer: metastatic triple-negative breast cancer.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Novel tool helps identify key targets to strengthen CAR NK cell therapies, MD Anderson research shows

Natural killer cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research from the University of Texas MD Anderson Cancer Center.

September 12, 2025

Vol.51 No.33

Drugs & Targets

FDA grants Fast Track designation for CER-1236 in AML

FDA has granted Fast Track designation to CER-1236 for Acute Myeloid Leukemia. CER-1236 is a therapy that engineers a cancer patient’s own T-cell therapeutics that deploy phagocytic mechanisms alongside the array of built-in target cell destroying mechanisms used by T-cells.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance

Cancer cells can break down the protective covers around nerves, causing nerve injury that triggers chronic inflammation leading to immune exhaustion and eventual resistance to immunotherapy, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.

September 05, 2025

Vol.51 No.32

In Brief

Elbert Kuo joins Baptist MD Anderson to lead the Division of Surgery

Elbert Y. Kuo, a thoracic surgeon who specializes in minimally invasive techniques, has joined Baptist MD Anderson Cancer Center as head of the Division of Surgery and surgeon-in-chief.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage 3 melanoma remained alive, according to new results from a study led by researchers at the University of Texas MD Anderson Cancer Center.

July 18, 2025

Vol.51 No.28

Menin inhibitors emerge as new treatment for advanced AML

YOU MAY BE INTERESTED IN

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Novel tool helps identify key targets to strengthen CAR NK cell therapies, MD Anderson research shows

FDA grants Fast Track designation for CER-1236 in AML

Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance

Elbert Kuo joins Baptist MD Anderson to lead the Division of Surgery

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

Renew today!

Subscriber content

Never miss an issue!

Login